It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
β thalassaemia intermedia (βTI) are a heterogeneous group of disorders known to be extremely phenotypically diverse. This group is more complex to manage as no definitive treatment guidelines exist unlike for β thalassaemia major (βTM). There are only a few studies looking at genotype phenotype associations of βTI outside the Mediterranean region. The reasons for the diverse clinical phenotype in βTI are unknown. We categorized fifty Sri Lankan patients diagnosed with βTI as mild, moderate or severe according to published criteria. DNA samples were genotyped for β thalassaemia mutations, α globin genotype and copy number and known genetic modifiers of haemoglobin F production. There were 26/50 (52.0%) in mild group and 12/50 (24.0%) each in moderate and sever categories. 18/26 (69.2%) classified as mild were β heterozygotes and 17/18 (94.4%) had excess α globin genes. 11/12 (91.6%) classified as moderate were β heterozygotes and 8/11 (72.2%) had excess α globin genes. In contrast, 8/12 (66.7%) classified as severe were β homozygotes and 7/8(87.5%) had α globin gene deletions. In Sri Lanka, co-inheritance of either excess α globin genes in β thalassaemia heterozygotes or α globin gene deletions in β thalassaemia homozygotes is a significant factor in modulating disease severity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
2 MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK; Centre for Tropical and Infectious Disease, Liverpool School of Tropical Medicine, Liverpool, UK
3 Hemal’s Thalassemia Care Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka
4 Faculty of Applied Sciences, Sabaragamuwa University of Sri Lanka, Belihulova, Sri Lanka
5 Faculty of Medicine, University of Sri Jayewardhanepura, Nugegoda, Sri Lanka
6 Centre for Tropical and Infectious Disease, Liverpool School of Tropical Medicine, Liverpool, UK
7 Department of Paediatric Haematology, King’s College Hospital, London, UK
8 Molecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, Rome, Italy
9 MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
10 Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka; Hemal’s Thalassemia Care Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka